Email This
Please enter a Recipient Address and/or check the Send me a copy checkbox.
Your email has been sent.
Your Name: 

Copy me on this email ()

Recipient's Email: 
Separate multiple email addresses with commas (Limit is 10).
Subject: 
Optional Message: 
Medicine's Fantastic Voyage

Creating A Medical Nanobot - Review: Cancer Nanomedicine-From Drug To Imaging

James Robb, MD, Pathology, 07:09AM Jan 30, 2014

Dear Colleagues, this recent excellent review of cancer nanomedicine should be in the file of everyone who is interested in this area. The review describes the current state of this exponentially developing field of medical nanobot creation and clinical application. E K-H Chow and D Ho, Cancer Nanomedicine: From Drug To Imaging, Science Translational Medicine, 2013;5:216rv4.

The abstract and Figure 2 are provided below. The tables provide an excellent list of the currently available cancer nanobots: Agent Delivered, Material(s), Translational Status, Key Details Of Study, and References.

The section headings of the review are: All About The Application, Conquering Cancer, Aiming At A Target, Capitalizing On Carbon, Silencing Genes, Pulling The Trigger, Immune System Plays Defense, Nano Gets A Better View, The Right Combination, and Future Steps For Nano.

Abstract: "Nanotechnology-based chemotherapeutics and imaging agents represent a new era of "cancer nanomedicine" working to deliver versatile payloads with favorable pharmacokinetics and capitalize on molecular and cellular targeting for enhanced specificity, efficacy, and safety. Despite the versatility of many nanomedicine-based platforms, translating new drug or imaging agents to the clinic is costly and often hampered by regulatory hurdles. Therefore, translating cancer nanomedicine may largely be application-defined, where materials are adapted only toward specific indications where their properties confer unique advantages. This strategy may also realize therapies that can optimize clinical impact through combinatorial nanomedicine. In this review, we discuss how particular materials lend themselves to specific applications, the progress to date in clinical translation of nanomedicine, and promising approaches that may catalyze clinical acceptance of nano."

   Credit: C. Bickel

Fig. 2. Designer nanomedicine. Nanomedicine platforms can take on any number of properties to tailor therapy or imaging, and improve chances of translation.

Thanks, Jim.

POLL ANSWER FOR 1/16/14 POLL: #5

no poll for this posting.

 

 

About This Blog

This blog will discuss new technologies that are entering the diagnostic and treatment arenas. Information given here is intended to help pathologists and laboratory technicians anticipate, understand, tolerate, accept, and subsequently implement these new technologies into their work.

Disclosure: James A. Robb, MD, has disclosed the following relevant financial relationships: Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Biomatrica, Inc.; Strategic Visions, Inc.
Received income in an amount equal to or greater than $250 from: Leidos Biomedical Research, Inc. (formerly SAIC-Frederick) Consulting Pathologist to the National Cancer Institute, NIH and The Research Institute at Nationwide Children's Hospital (NCI-TCGA).
Poll: The drug piceatannol, which was delivered to the adhered PMNs, inhibits which of the following pathways? 1) The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) pathway|2) The Cy5-FcGamma endocytotic pathway|3) The "outside-in" beta-2 integrin signaling pathway via the FcGamma pathway|4) The "outside-in" beta-2 integrin signaling pathway via the Syk phosphorylation pathway|5) #1 and #3 are correct.|

  • James Robb

    Dr. Robb is board certified in anatomic pathology, clinical pathology, cytopathology, and dermatopathology. Dr. Robb is currently a Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc) consulting pathologist to the National Cancer Institute, NIH, HHS. He has been Senior Surgeon at NIH, Professor of Pathology at University California at San Diego; staff pathologist at Scripps Clinic, La Jolla, California; Director of Anatomic and Molecular Pathology, Cedars MC, Miami, Florida; and Medical Director of the HCA East Florida Divisions Integrated Regional Laboratories system, and College of American Pathologists governor.

 
Social Bookmarking
Add this blog post to your favorite Social Bookmarking site.
  • ADD TO FACEBOOK 


 
All material on this website is protected by copyright, Copyright © 1994-2014 by WebMD LLC. This website also contains material copyrighted by 3rd parties.